References
- Dang CV. MYC on the path to cancer. Cell 2012;149:22–35.
- Salaverria I, Siebert R. The gray zone between Burkitt's lymphoma and diffuse large B-cell lymphoma from a genetics perspective. J Clin Oncol 2011;29:1835–1843.
- Crowther-Swanepoel D, Broderick P, Di Bernardo MC, . Common variants at 2q37.3, 8q24.21, 15q21.3 and 6q24.1 influence chronic lymphocytic leukemia risk. Nat Genet 2010;42:132–136.
- Zhang W, Kater AP, Widhopf GF 2nd, . B-cell activating factor and v-Myc myelocytomatosis viral oncogene homolog (c-Myc) influence progression of chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2010;107:18956–18960.
- Fabbri G, Rasi S, Rossi D, . Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med 2011;208:1389–1401.
- Krysov S, Dias S, Paterson A, . Surface IgM stimulation induces MEK1/2-dependent MYC expression in chronic lymphocytic leukemia cells. Blood 2012;119:170–179.
- Herishanu Y, Pérez-Galán P, Liu D, . The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 2011;117:563–574.
- Huh YO, Lin KI, Vega F, . MYC translocation in chronic lymphocytic leukaemia is associated with increased prolymphocytes and a poor prognosis. Br J Haematol 2008;142:36–44.
- Edelmann J, Holzmann K, Miller F, . High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations. Blood 2012;120:4783–4794.
- Brown JR, Hanna M, Tesar B, . Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia. Clin Cancer Res 2012;18:3791–3802.
- Rossi D, Spina V, Deambrogi C, . The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood 2011;117:3391–3401.
- Cascón A, Robledo M. MAX and MYC: a heritable breakup. Cancer Res 2012;72:3119–3124.
- Puente XS, Pinyol M, Quesada V, . Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011;475:101–105.
- de Paoli L, Cerri M, Monti S, . MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia. Leuk Lymphoma 2013;54;1087–1090.
- Delmore JE, Issa GC, Lemieux ME, . BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011;146: 904–917.